Welcure Drugs & Pharmaceuticals Ltd
Incorporated in 1992, Welcure Drugs And Pharmaceuticals Ltd used to manufacture pharmaceuticals products[1]
- Market Cap ₹ 10.9 Cr.
- Current Price ₹ 8.07
- High / Low ₹ 8.07 / 3.76
- Stock P/E
- Book Value ₹ 5.05
- Dividend Yield 0.00 %
- ROCE -12.3 %
- ROE -24.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company's working capital requirements have reduced from 74.6 days to 45.4 days
Cons
- Company has low interest coverage ratio.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | |
|---|---|---|---|
| 16.36 | 24.67 | 25.67 | |
| 17.92 | 25.91 | 27.68 | |
| Operating Profit | -1.56 | -1.24 | -2.01 |
| OPM % | -9.54% | -5.03% | -7.83% |
| 0.59 | 1.14 | 1.08 | |
| Interest | 0.36 | 0.24 | 0.53 |
| Depreciation | 0.48 | 0.43 | 0.43 |
| Profit before tax | -1.81 | -0.77 | -1.89 |
| Tax % | 4.42% | 11.69% | 2.12% |
| -1.89 | -0.86 | -1.93 | |
| EPS in Rs | -1.40 | -0.64 | -1.43 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -124% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 69% |
| 3 Years: | -6% |
| 1 Year: | 102% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | |
|---|---|---|---|
| Equity Capital | 12.11 | 12.11 | 12.12 |
| Reserves | -2.49 | -3.36 | -5.29 |
| 3.79 | 3.73 | 2.76 | |
| 4.74 | 7.01 | 7.76 | |
| Total Liabilities | 18.15 | 19.49 | 17.35 |
| 6.70 | 6.41 | 6.02 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.38 | 0.38 | 0.28 |
| 11.07 | 12.70 | 11.05 | |
| Total Assets | 18.15 | 19.49 | 17.35 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | |
|---|---|---|---|
| -1.66 | 0.39 | 1.29 | |
| -1.22 | -0.14 | 0.08 | |
| 2.97 | -0.28 | -1.43 | |
| Net Cash Flow | 0.09 | -0.03 | -0.06 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2006 | Mar 2007 | Mar 2008 | |
|---|---|---|---|
| Debtor Days | 112.67 | 119.40 | 123.56 |
| Inventory Days | 75.70 | 28.81 | 12.58 |
| Days Payable | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 188.37 | 148.20 | 136.14 |
| Working Capital Days | 110.21 | 68.35 | 45.36 |
| ROCE % | -4.09% | -12.32% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Newspaper Clipping of Unaudited Financials Results of Quarter and Half Year Ended September 30, 2024.
-
Submission Of Half Yearly Disclosures On Related Party Transactions For A Period From 1St April, 2024 To 30Th September, 2024
14 Nov - Submission of half yearly disclosures on related party transactions.
- Unaudited Financial Results Of The Company Along With The Limited Review Report As Issued By Statutory Auditor Of The Company For The 2Nd Quarter And Half Year Ended On 30Th September 2024. 14 Nov
-
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Welcure Drugs & Pharmaceuticals Limited
Held On Today I.E. Thursday, 14Th November, 2024.
14 Nov - Board approved unaudited financial results for Q2 2024.
-
Board Meeting Intimation for Postponement Of Board Meeting
13 Nov - Board meeting postponed to November 14, 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Company manufactures and markets pharmaceuticals formulations in the form of tablets, capsules, dry syrups, antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarial, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilizers, sedatives and gastrointestinal.